Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Vaughn B. Himes, insider at Seagen

Vaughn B. Himes Insider Information

Insider of Seagen

Vaughn has more than 25 years of experience in product development and commercialization at large pharmaceutical and biotechnology companies. With deep operational expertise, he leads manufacturing, supply chain, process sciences, and quality functions for Seagen. Vaughn has played a pivotal role in the successful commercialization of our marketed products and the development of our robust pipeline of product candidates.

Previously, Vaughn spent 20 years in biotech leadership roles, including as the Senior Vice President of Technical Operations at ZymoGenetics (later acquired by Bristol Myers Squibb), where he oversaw commercial and clinical manufacturing, supply chain and logistics, quality control, and process development. Vaughn also spent 10 years in the pharmaceutical industry at Wyeth (now Pfizer).

Vaughn holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.A. in Chemistry from Pomona College.

What is Vaughn B. Himes' net worth?

The estimated net worth of Vaughn B. Himes is at least $21.32 million as of June 17th, 2022. Dr. Himes owns 119,471 shares of Seagen stock worth more than $21,321,989 as of June 29th. This net worth estimate does not reflect any other investments that Dr. Himes may own. Learn More about Vaughn B. Himes' net worth.

How old is Vaughn B. Himes?

Dr. Himes is currently 61 years old. There are 4 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer & Interim CEO, who is 66 years old. Learn More on Vaughn B. Himes' age.

How do I contact Vaughn B. Himes?

The corporate mailing address for Dr. Himes and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected] Learn More on Vaughn B. Himes' contact information.

Has Vaughn B. Himes been buying or selling shares of Seagen?

In the last ninety days, Vaughn B. Himes has sold $1,667,800.14 in Seagen stock. Most recently, on Wednesday, June 29th, 0 shares of BMO Capital Markets stock. Learn More on Vaughn B. Himes' trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 42 times. They sold a total of 726,629 shares worth more than $115,625,220.08. The most recent insider tranaction occured on June, 17th when insider Vaughn B Himes sold 1,134 shares worth more than $181,440.00. Insiders at Seagen own 27.3 % of the company. Learn More about insider trades at Seagen.

Information on this page was last updated on 6/17/2022.

Vaughn B. Himes Insider Trading History at Seagen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2022Sell1,134$160.00$181,440.00119,471View SEC Filing Icon  
5/24/2022Sell10,866$136.79$1,486,360.1459,064View SEC Filing Icon  
3/3/2022Sell12,000$127.05$1,524,600.00View SEC Filing Icon  
12/20/2021Sell345$149.85$51,698.25View SEC Filing Icon  
11/11/2021Sell6,000$178.63$1,071,780.00View SEC Filing Icon  
9/8/2021Sell6,000$150.00$900,000.00View SEC Filing Icon  
8/16/2021Sell658$154.55$101,693.90View SEC Filing Icon  
6/7/2021Sell1,303$150.00$195,450.00View SEC Filing Icon  
6/3/2021Sell10,697$144.91$1,550,102.2772,894View SEC Filing Icon  
3/2/2021Sell12,000$153.22$1,838,640.00View SEC Filing Icon  
12/7/2020Sell8,000$181.76$1,454,080.00View SEC Filing Icon  
9/9/2020Sell8,000$147.55$1,180,400.00View SEC Filing Icon  
7/17/2020Sell8,000$179.42$1,435,360.00199,840View SEC Filing Icon  
3/6/2020Sell8,000$114.91$919,280.00View SEC Filing Icon  
12/6/2019Sell8,000$117.16$937,280.00View SEC Filing Icon  
8/30/2019Sell8,000$72.86$582,880.00View SEC Filing Icon  
8/28/2019Sell6,836$73.21$500,463.56View SEC Filing Icon  
5/31/2019Sell8,000$65.94$527,520.00View SEC Filing Icon  
3/8/2019Sell8,000$68.72$549,760.00View SEC Filing Icon  
11/30/2018Sell5,000$62.14$310,700.00View SEC Filing Icon  
9/7/2018Sell5,000$76.99$384,950.00View SEC Filing Icon  
8/27/2018Sell5,530$74.23$410,491.90View SEC Filing Icon  
5/31/2018Sell5,000$58.47$292,350.00View SEC Filing Icon  
3/15/2018Sell5,000$58.12$290,600.00View SEC Filing Icon  
11/30/2017Sell10,000$59.97$599,700.00View SEC Filing Icon  
9/8/2017Sell10,000$53.22$532,200.00View SEC Filing Icon  
8/28/2017Sell6,377$47.89$305,394.53View SEC Filing Icon  
3/31/2017Sell10,000$62.75$627,500.00161,283View SEC Filing Icon  
12/7/2016Sell30,000$65.32$1,959,600.00View SEC Filing Icon  
8/22/2016Sell3,991$46.59$185,940.69View SEC Filing Icon  
12/15/2015Sell40,500$39.94$1,617,570.0076,212View SEC Filing Icon  
8/20/2015Sell5,997$42.02$251,993.9476,212View SEC Filing Icon  
11/12/2014Sell10,000$37.52$375,200.00View SEC Filing Icon  
6/13/2013Sell10,000$32.11$321,100.00View SEC Filing Icon  
See Full Table

Vaughn B. Himes Buying and Selling Activity at Seagen

This chart shows Vaughn B Himes's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $178.47
Low: $175.61
High: $181.10

50 Day Range

MA: $142.08
Low: $108.81
High: $179.33

2 Week Range

Now: $178.47
Low: $105.43
High: $192.79

Volume

1,468,975 shs

Average Volume

1,249,163 shs

Market Capitalization

$32.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.